Virtual Library
Start Your Search
Y. Ohshio
Author of
-
+
P3.02 - Biology/Pathology (ID 620)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.02-003 - Tissue and Serum Levels of Galectin-3 in NSCLC Patients (ID 8723)
09:30 - 09:30 | Author(s): Y. Ohshio
- Abstract
Background:
Galectin-3 is a β-galactoside binding lectin, which is associated with cell proliferation, cell adhesion, apoptosis, angiogenesis and metastasis in several types of malignancies. However, the role of galectin-3 in the prognosis of lung cancer remains to be elucidated. In this study, we examined whether tissue expression and serum level of galectin-3 could serve as a prognostic marker in NSCLC.
Method:
Galectin-3 expression was analyzed by immunohistochemistry for 42 NSCLC patients who had undergone the radical surgery between 2014 and 2016. Serum galectin-3 level was assessed before surgery and 1 month after surgery by the enzyme-linked immunosorbent assay method.
Result:
Galectin-3 expression was observed in 14 patients (33.3%), and significantly associated with the incidence of recurrences (p<0.001) and the relapse-free survival time (p<0.001). Serum galectin-3 level was not reduced after radical resection, and there was no significant correlation between tissue expression and serum level of galectin-3.
Conclusion:
These data suggest that galectin-3 expression on tumor cells would serve as a prognostic marker in NSCLC, but serum galectin-3 level has no prognostic role on recurrence.
